Contentious role of ‘Good Adiponectin’ in pulmonary and cardiovascular diseases: Is adiponectin directed therapy a boon or a bane?

摘要: After two decades of its discovery, numerous facts adiponectin (APN) biology has been uncovered, yet, APN remains an elusive adipokine. Findings from clinical studies and animal models established APN's ameliorative role in cardiovascular disease (CVD) pulmonary (PD) but the same condition is prognostic for mortality set patients which cornered towards a dubious state. A repertoire mechanisms associated with positive association both lean/cachectic or obese CVD PD past publications are evaluated. Newer pharmacological agent may be explored to regulate elevated blood concentration COPD CHF whereas administration recombinant as well growth hormone augment subjects low intracellular concentration. However, some directed therapy pre-clinical setup pronounced contentious effects. reviewing functioning pathologic conditions lean conditions, authors came conclusion that utilized caution keeping mind different age group, sex diseases they suffering from.